Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA) -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (1744)	12/25/2003 8:18:08 PM
From: puborectalis	Read Replies (1) \| Respond to of 1870

For those who can't resist a drug stock, Samuel D. Isaly, portfolio manager at the Eaton Vance Worldwide Health Sciences Fund, suggests Novartis (NVS ), a Swiss company he says will see earnings growth of 15% in 2004 as it profits from cancer treatments such as Gleevec for chronic myeloid leukemia and Femara for advanced breast cancer. Isaly says Novartis, recently trading at $44, could top $50 in 2004 as earnings increase and investors discover this overlooked stock.